Brighton Jones LLC Purchases Shares of 3,450 CRISPR Therapeutics AG (NASDAQ:CRSP)

Brighton Jones LLC bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,450 shares of the company’s stock, valued at approximately $216,000.

Other hedge funds have also recently made changes to their positions in the company. CWM LLC boosted its stake in shares of CRISPR Therapeutics by 80.7% during the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after purchasing an additional 260 shares in the last quarter. Tradewinds Capital Management LLC increased its holdings in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after buying an additional 600 shares in the last quarter. Blue Trust Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $32,000. Headlands Technologies LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $34,000. Finally, Bourgeon Capital Management LLC grew its position in shares of CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of analyst reports. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Royal Bank of Canada boosted their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Wells Fargo & Company boosted their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, February 22nd. Morgan Stanley upped their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, February 26th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Stock Up 1.5 %

Shares of CRSP stock opened at $55.89 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The firm’s 50 day moving average price is $67.75 and its two-hundred day moving average price is $64.17. The stock has a market cap of $4.74 billion, a price-to-earnings ratio of -28.52 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. CRISPR Therapeutics’s quarterly revenue was up 3253.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.41) EPS. On average, equities analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the sale, the chief executive officer now owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold 83,992 shares of company stock worth $6,132,335 in the last three months. 4.10% of the stock is owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.